The EAS Executive Committee has identified additional interesting perspectives and lenses through which the current guidelines can be interpreted. These are outlined below:

Atherosclerosis develops when apoB-containing lipoproteins, especially LDL, accumulate in the artery wall, triggering inflammation and plaque formation. This process can progress to plaque rupture and cardiovascular events. Lowering LDL reduces lipid accumulation, slows inflammation, and lowers the risk of rupture and acute events.